Navigation Links
Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Date:9/1/2009

TUSTIN, Calif., Sept. 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009 at 10:25 am EDT. The conference will be held at the New York Palace Hotel in New York City.

A live webcast of the company's presentation will be available at the Investors section of Peregrine's website at www.peregrineinc.com. A replay will be available on the Peregrine website and archived for 90 days.

For more information about this conference, please visit: http://www.rodmanandrenshaw.com/conferences?id=30

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                               Media
    info@peregrineinc.com                                   Jennifer Anderson
    (800) 987-8256                                          (212) 918-4642


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
2. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
3. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
4. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
5. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
6. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
7. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
8. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
9. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
10. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
11. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017 /PRNewswire/ - The Fight Against Cancer ... Research (OICR) are pleased to report that Fusion Pharmaceuticals ... with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) ... groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as ... ...
(Date:2/23/2017)... -- In Atlanta, it seems everyone has a chance to express ... an expressive and dynamic community unlike any other. The businesses ... it. With their newest salon in ... carry on that tradition with a unique, fresh approach to ... is the newest of 13 nationwide locations, each of them ...
(Date:2/23/2017)... 2017  Imanis Life Sciences announced today the ... vaccinia viruses for virotherapy research. These viruses are ... proprietary, vaccinia virus-based technology platform for research use. ... a partnership with Genelux to offer researchers, for ... use in research," said Dr. Kah Whye ...
(Date:2/23/2017)... ... February 23, 2017 , ... Baltimore ... multiple immunoassay-based threat detection technologies by researchers from the Pacific National Northwest ... detection technology was found to have the best level of detection (LOD) ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 7, 2017 The biometrics ... by the confluence of organizations, desires to better ... knowledge-based systems (password and challenge questions), biometrics is ... government systems. The market is driven by use ... between consumer and enterprise uses cases, with consumer-facing ...
(Date:2/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the LEERINK Partners 6th Annual Global Healthcare Conference ... February 15, 2017 at 10 a.m. Eastern Time. ... be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/3/2017)...  Texas Biomedical Research Institute announced that its Board of ... as the Institute,s new President and CEO. Dr. Schlesinger will ... He is currently the Chair of the Department of Microbial ... Interface Biology at Ohio State University. "We are ... CEO of Texas Biomed," said Dr. James O. Rubin ...
Breaking Biology News(10 mins):